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Summary
Objective: Copy number variations (CNVs) represent a significant genetic risk for 
several neurodevelopmental disorders including epilepsy. As knowledge increases, 
reanalysis of existing data is essential. Reliable estimates of the contribution of CNVs 
to epilepsies from sizeable populations are not available.
Methods: We assembled a cohort of 1255 patients with preexisting array compara-
tive genomic hybridization or single nucleotide polymorphism array based CNV 
data. All patients had “epilepsy plus,” defined as epilepsy with comorbid features, 
including intellectual disability, psychiatric symptoms, and other neurological and 
nonneurological features. CNV classification was conducted using a systematic fil-
tering workflow adapted to epilepsy.
Results: Of 1097 patients remaining after genetic data quality control, 120 individuals 
(10.9%) carried at least one autosomal CNV classified as pathogenic; 19 individuals 
(1.7%) carried at least one autosomal CNV classified as possibly pathogenic. Eleven 
patients (1%) carried more than one (possibly) pathogenic CNV. We identified CNVs 
covering recently reported (HNRNPU) or emerging (RORB) epilepsy genes, and fur-
ther delineated the phenotype associated with mutations of these genes. Additional 
novel epilepsy candidate genes emerge from our study. Comparing phenotypic features 
of pathogenic CNV carriers to those of noncarriers of pathogenic CNVs, we show that 
patients with nonneurological comorbidities, especially dysmorphism, were more 
likely to carry pathogenic CNVs (odds ratio = 4.09, confidence interval = 2.51- 6.68; 
P = 2.34 × 10−9). Meta- analysis including data from published control groups showed 
that the presence or absence of epilepsy did not affect the detected frequency of CNVs.
Significance: The use of a specifically adapted workflow enabled identification of 
pathogenic autosomal CNVs in 10.9% of patients with epilepsy plus, which rose to 
12.7% when we also considered possibly pathogenic CNVs. Our data indicate that 
epilepsy with comorbid features should be considered an indication for patients to be 
selected for a diagnostic algorithm including CNV detection. Collaborative large- 
scale CNV reanalysis leads to novel declaration of pathogenicity in unexplained 
cases and can promote discovery of promising candidate epilepsy genes.
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1 |  INTRODUCTION
Current estimates suggest that genetics contribute to causa-
tion in 50%- 70% of the epilepsies.1 Copy number variations 
(CNVs) represent a prominent type of variant carrying risk 
for certain epilepsies.2–5 Whole genome oligonucleotide 
array CGH or SNP array is routinely included in evalua-
tion of patients with complex phenotypes with a suspected 
genetic cause.6 CNVs, as a risk factor or cause, have been 
reported in ~5%- 12% of patients with different types of 
epilepsies.2,4,5,7–9 The risk of a pathogenic CNV is report-
edly increased with concurrent intellectual disability (ID), 
dysmorphic features, autism spectrum disorder (ASD), drug 
resistance, or other comorbidities, from a study of 222 pa-
tients.10 Recurrent CNV “hotspots” predispose to different 
types of epilepsies.5,11 CNV detection has pointed to novel 
epilepsy genes.12
Robust estimates of the frequencies and types of putatively 
relevant CNVs in epilepsy are needed to determine whether 
CNV detection should be included in genetic evaluation of 
patients with various epilepsy phenotypes. As knowledge of 
epilepsy genetics increases, systematic, iterative reevaluation 
of genetic data becomes essential. This process requires large 
numbers of individuals to be corralled, and because such data 
will inevitably come from different centers using different 
technologies, a robust means of joint reevaluation is essential.
Epilepsy is often a feature of neurodevelopmental disor-
ders (NDDs). A recent study on individuals with NDDs and 
epilepsy reported similar results for rare variant frequency 
for individuals ascertained to have epileptic encephalopathy 
(EE) and for individuals ascertained for NDDs with unspec-
ified epilepsy,13 suggesting that, genetically, epilepsy can be 
considered part of the spectrum of NDDs. Looking at this 
concept from the perspective of CNV, and to determine the 
frequency of CNVs in particular epilepsy phenotypes, we 
assembled a large international cohort of patients with the 
phenotype of “epilepsy plus,” which we define as the oc-
currence of epilepsy and comorbid features, including ID 
and psychiatric, neurological, and nonneurological features. 
Preexisting array data were systematically investigated using 
a workflow based on current knowledge of CNV classifica-
tion. The workflow enabled combination of multicenter CNV 
data to provide a robust, up- to- date reevaluation of the contri-
bution of CNVs to epilepsy plus and identified new candidate 
pathogenic autosomal CNVs. The method can be applied it-
eratively with additional cohorts at future time points, mak-
ing optimal use of existing data.
2 |  MATERIALS AND METHODS
2.1 | Ethics
This study was approved by the ethics committees of the par-
ticipating centers. Written informed consent was provided by 
the patient, or the parent or the guardian of each patient as 
appropriate.
2.2 | Data collection
Preexisting CNV data, derived from array CGH or SNP array 
conducted for clinical or research purposes, were collected 
from eight specialist epilepsy and/or genetic centers (Table 
S1). All patients also had comorbid features including ID, 
autism, dysmorphic features, other neurological or nonneu-
rological conditions, structural brain abnormalities, or multi-
drug resistance.14 Clinical information was collected through 
referring clinicians. Seizure and epilepsy/syndrome types 
were classified according to the International League Against 
Epilepsy criteria when available.15
2.3 | CNV analysis: Quality control and 
classification
All CNV calls were provided by the contributing centers 
(Table S1). Figure 1 shows the workflow we used to classify 
CNVs (Data S1). We focused only on autosomal CNVs due 
to higher quality of CNV calls from nonsex chromosomes.16 
K E Y W O R D S
array CGH, copy number variants, epilepsy genes, SNP array
Key Points
• CNV is an important contributor to the causation 
of epilepsy plus, with pathogenic and possibly 
pathogenic CNVs present in nearly 13% of cases
• The use of a specifically adapted workflow to 
classify CNVs allows the analysis of data from 
retrospectively collected patients screened through 
different platforms
• This study highlights CNVs covering recently re-
ported (HNRNPU) or emerging (RORB) epilepsy 
genes, and further delineates the associated 
phenotype
• Patients with nonneurological comorbidities, es-
pecially dysmorphism, were more likely to carry 
pathogenic CNVs
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To ensure high reliability, we considered only CNVs with 
high calling confidence according to the following criteria: 
(1) size ≥ 150 kb, (2) coverage of ≥30 consecutive probes 
for SNP arrays and ≥3 probes for array CGH, and (3) micro-
deletion/microduplication frequency < 1% in the entire study 
sample. Samples with a total number of deletion or dupli-
cation (or both) calls >2 SD from the mean number of any 
calls/sample across the entire dataset were excluded from the 
analysis. Further manual analysis used a bespoke workflow 
based on current understanding of classification,17,18 includ-
ing the American College of Medical Genetics guidelines19 
and additional literature.2–6,11 CNVs were classified into four 
groups: pathogenic, possibly pathogenic, benign, or of un-
known significance. Briefly, the workflow was as follows: 
First, common CNVs, present in the healthy population,20 
were classified as “benign.” All remaining CNVs were then 
classified as “pathogenic” if they met the following criteria: 
≥80% overlap of the study CNV with any CNVs known to 
be associated with epilepsy; or, CNV with a size ≥ 3 Mb; 
or, CNV with a size < 3 Mb and > 1 Mb, and with de novo 
occurrence. The remaining CNVs were further classified ac-
cording to their gene content. A CNV was classified as path-
ogenic when it involved a gene known to be associated with 
epilepsy (Table S2), the phenotype was concordant with that 
in the literature, and the type of CNV (deletion/duplication) 
matched current knowledge on the pathogenic mechanism of 
the gene change (gain or loss of function). If a CNV con-
tained a gene associated with epilepsy but the other condi-
tions were not fulfilled, the CNV was considered pathogenic 
only if proven to be de novo and was otherwise classified as 
“possibly pathogenic.” CNVs containing a brain- expressed 
gene, according to the published datasets21 and the database 
GTEx (http://www.gtexportal.org/home/), were classified as 
“possibly pathogenic” only if de novo. Analysis of recessive 
F I G U R E  1  Workflow used to classify the copy number variations (CNVs) in our cohort of patients with epilepsy plus. Stepwise procedures 
are shown for CNV classification into benign, pathogenic, possibly pathogenic, and unknown significance groups. CGH, comparative genomic 
hybridization; CNS, central nervous system; SNP, single nucleotide polymorphism
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inheritance of epilepsy genes was not considered due to limi-
tations of most CNV platforms on calling homozygous dele-
tions or duplications. The remaining CNVs were classified as 
“of unknown significance.”
2.4 | CNV confirmation
In each individual, the proposed possibly pathogenic CNVs 
were confirmed if DNA was available and inheritance status 
was confirmed using a second, locally developed technique for 
multiplex amplicon quantification (MAQ; Data S1; Agilent, 
https://www.agilent.com/en/products/next-generation-
sequencing/amplicon-target-amplification-(multiplicom)/
maq-overview).
2.5 | Phenotype enrichment analysis
Using Fisher's exact test, we investigated whether patients 
carrying a pathogenic autosomal CNV, compared to those 
not carrying a pathogenic CNV, had overrepresentation 
for specific phenotype components (nonneurological dis-
orders, neurological or psychiatric disorder, ID, facial dys-
morphism, brain abnormalities, epilepsy onset < 1 year of 
age, and EE). The analysis was conducted in two ways—
(1) for any pathogenic CNV and (2) for only large (>1 Mb) 
pathogenic CNVs—and was corrected for multiple testing 
accordingly.
2.6 | Meta- analysis
To determine the impact of epilepsy on the probability of 
identifying pathogenic CNVs, we used the following strat-
egy. First, we split our cohort into two subgroups including 
patients with (1) epilepsy and ID including autistic features 
and (2) epilepsy and other psychiatric/neurological disor-
ders. We gathered two “historical control groups” through 
a systematic review of the literature and a meta- analysis and 
estimated the yield of pathogenic CNVs in patients with 
(1) ID including autistic features (without epilepsy) and (2) 
psychiatric/neurological disorders (without epilepsy). Then, 
we compared the yield of pathogenic CNVs between these 
groups with (1) epilepsy and ID including autistic features 
versus the historical- control group with only ID and autistic 
features and (2) epilepsy with other psychiatric/neurological 
disorders versus the corresponding control group from the lit-
erature manifesting only other psychiatric/neurological dis-
orders. We used the Cochran Q test to assess heterogeneity 
across studies.
To evaluate whether epileptic encephalopathies might 
specifically contribute to the yield of pathogenic CNVs, we 
compared patients with epilepsy manifesting as EE (epilep-
sy- EE) from our cohort to those with epilepsy without EE 
(epilepsy- notEE) from a systematic review of the literature.
The full search strategy, inclusion criteria, and methods 
are available in Data S1.
3 |  RESULTS
We assembled a cohort of 1255 patients. After quality con-
trol, 1097 patients were retained for analysis. Of these, 139 
(12.7%) carried a total of 142 autosomal CNVs classified as 
either pathogenic (n = 122, 10.9%) or possibly pathogenic 
(n = 20, 1.7%). Eleven patients (1%) carried two pathogenic 
or possibly pathogenic CNVs (Table S3).
3.1 | Pathogenic CNVs
To simplify presentation, we further divided pathogenic 
CNVs into four subgroups: (1) recurrent CNVs with well- 
documented enrichment in epilepsy; (2) CNVs related to 
a genetic Online Mendelian Inheritance in Man database 
(OMIM) syndrome with neurological symptoms in which 
epilepsy can feature; (3) CNVs not known to be enriched in 
epilepsy and not associated with any other OMIM syndrome, 
but containing at least one gene that is already implicated in 
epilepsy; and (4) CNVs based on size combined with de novo 
occurrence.
3.1.1 | Recurrent CNVs with  
well- documented enrichment in epilepsy
Thirty- six individuals had a CNV known to be recurrent in 
people with epilepsy (36/120, 30%; Table 1).2,5,11 One indi-
vidual had two recurrent pathogenic CNVs. The 16p13.11 
deletion was the most frequent, occurring in 10 of 120 (8.3%) 
patients bearing pathogenic CNVs and 10 of 1097 (0.9%) of 
the studied individuals. Other frequently represented CNVs 
were 1p36 deletion (OMIM #607872, 5/120 patients, 4.2%), 
15q11.2 deletion (OMIM #615656, 5/120 patients, 4.2%), 
and 22q11.219 duplication (OMIM #608363, 5/120 patients, 
4.2%).
3.1.2 | CNVs related to a genetic OMIM 
syndrome with neurological symptoms in 
which epilepsy can feature
Thirty- three individuals had pathogenic CNVs (33/120, 
27.5%) mapping to regions for well- characterized genetic 
syndromes associated with neurological features including 
epilepsy (Table S4a) and consistent with the relevant syn-
drome. The most frequent were as follows: the Williams- 
Beuren 7q11.23 deletion syndrome (five patients), 15q11.2 
duplication syndrome, distal (three patients), 16p11.2 du-
plication syndrome including PRRT2 (four patients), the 
Potocki- Lupski 17p11.2 duplication syndrome (two patients), 
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and 17p13.3 deletion syndrome, also known as Miller- Dieker 
lissencephaly deletion syndrome (three patients). We also 
identified de novo duplications at 2q24.322 and at 4p16.3-
 p13,23 for which regions both deletions and reciprocal dupli-
cations have been associated with epilepsy.22,23
3.1.3 | CNVs including epilepsy- 
related genes
Nineteen individuals had a CNV (19/120, 15.8%) includ-
ing epilepsy- related genes (Table 2). Five individuals had a 
CNV including HNRNPU (four de novo deletions and one 
duplication; two deletions and the duplication also contained 
the flanking AKT3 gene). The four probands carrying dele-
tions presented with epilepsy classified as Lennox- Gastaut 
syndrome in one patient, genetic generalized epilepsy (GGE) 
in another, and early onset, drug- resistant epilepsy not other-
wise classified in the remaining two. Moderate to severe ID 
was reported in four patients and one also had ASD. Three 
had microcephaly, congenital and severe (−4 SD) in one. 
Brain magnetic resonance imaging showed corpus callosum 
agenesis or hypoplasia in three of four patients. Facial dys-
morphic features were observed in three patients. The patient 
carrying a large (>100 Mb) duplication involving, among 
many other genes, HNRNPU and AKT3, had a complex phe-
notype including neonatal seizure onset, polymicrogyria, and 
multiple cardiac defects. Three individuals had a 9q21.13 de-
letion, one de novo and two of unknown inheritance, includ-
ing a gene with recently described association with epilepsy, 
RORB. All the patients presented with ID and generalized 
epilepsy with absences or atypical absences, with eyelid 
myoclonia in two cases and photosensitivity in one. Further 
clinical details of patients with CNVs including HNRNPU 
or RORB are provided in Tables S5a and S5b. Three dele-
tions encompassed the ADGRV1 gene, two of which included 
MEF2C. Additional epilepsy genes that were found deleted 
or duplicated in single patients are listed in Table 2 and in-
clude GNAO1, NEDD4L, and SIK1.
3.1.4 | Pathogenic autosomal CNVs based 
on size combined with de novo occurrence
Thirty- two individuals (32/120, 26.6%) had CNVs that fell 
only into this category (one individual had two large patho-
genic CNVs). We did not find overlapping CNVs in healthy 
individuals (Database of Genomic Variants; http://dgv.tcag.
ca/dgv/app/home). Sixteen (16/32, 50%) of the CNVs ≥ 3 Mb 
showed an overlap or partial overlap with CNVs described in 
Decipher (https://decipher.sanger.ac.uk/) in patients exhibiting 
various clinical features including ID, seizures, and dysmor-
phisms (Table S4b). Interestingly, in a patient with an EE, we 
uncovered a de novo 13q33.1- q13.3 deletion including NBEA.
3.2 | Possibly pathogenic CNVs
Nineteen individuals (19/1097, 1.73%) had a total of 20 
CNVs classified as possibly pathogenic (one individual had 
two possibly pathogenic CNVs); 10 were de novo (Table 3). 
For 17 of 19 individuals (18/20 CNVs), DNA was available 
to check the CNV and/or inheritance using MAQ analysis. 
Eleven of the 18 analyzed CNVs were confirmed; in seven 
cases, the test was inconclusive (Table 3). These CNVs were 
classified as possibly pathogenic because they included 
an epilepsy gene but were inherited or the direction of the 
change was not concordant with the known disease mecha-
nism (loss or gain of function) or phenotype, or because they 
included a brain- expressed gene and were de novo. CNVs 
falling in the first category were a maternally inherited 10q23 
deletion including LGI1, and a maternally inherited 20q13 
duplication including KCNQ2, CHRNA4, and EEF1A2. Four 
other inherited CNVs included recessive genes: PLCB1, 
TBC1D24, ABAT, and CNTNAP2. A possible additional 
T A B L E  1  Recurrent CNVs with well- documented enrichment in epilepsy
Samples, 
n Chr region CNV type Syndrome OMIM/reference boundaries
OMIM or 
references
5 1p36 Deletion Chromosome 1p36 deletion syndrome 1:1- 27 600 000 #607872
2 1q21.1 Deletion Chromosome 1q21.1 deletion syndrome 1:143 200 000- 147 500 000 #612474
1 1q21.1 Duplication Chromosome 1q21.1 duplication syndrome 1:143 200 000- 147 500 000 #612475
5 15q11.2 Deletion Chromosome 15q11.2 deletion syndrome 15:20 500 000- 25 500 000 #615656
3 15q13.3 Deletion Chromosome 15q13.3 deletion syndrome 15:30 900 000- 33 400 000 #612001
3 16p11.2 Deletion Chromosome 16p11.2 deletion syndrome 16:28 500 000- 35 300 000 #611913
10 16p13.11 Deletion Chromosome 16p13.11 deletion syndrome 16:15 000 000- 16 300 000 Refs 3, 4
3 22q11.21 Deletion Chromosome 22q11.2 deletion syndrome, 
distal
22:17 400 000- 25 500 000 #611867
5 22q11.21 Duplication Chromosome 22q11.2 duplication syndrome 22:17 400 000- 25 500 000 #608363
CNV, copy number variation; OMIM, Online Mendelian Inheritance in Man database.
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single nucleotide variant (SNV) on the other allele cannot be 
excluded. Of note, the PLCB1 deletion was confirmed to be 
homozygous and would be considered pathogenic, but our 
flowchart was not developed for recessive analysis.
In the second category, we identified several interest-
ing candidate genes including a de novo deletion including 
STAG1 and a de novo intragenic duplication in FGF12. In 
both genes, only recently have pathogenic SNVs been re-
ported in patients with neurodevelopmental disorders includ-
ing epilepsy.24,25 We further identified a deletion including 
SETBP1 associated with Shinzel-Gieidon syndrome and ID 
(OMIM 611060) and a duplication including HCN2, a gene 
in which SNVs exerting a gain- of- function effect have re-
cently been suggested as a risk factor for genetic generalized 
epilepsies.26 HCN2 has also previously been associated with 
febrile epilepsy syndromes; interestingly, the patient carrying 
this CNV also had a history of febrile seizures.27 Other inter-
esting candidate genes located in identified de novo deletions 
or possibly disrupted by intragenic breakpoints of identi-
fied duplications included FMN2 (also associated with AR 
mental retardation MIM616193), CHRM3, CSNK1G3, and 
NMT1, all of which are brain- expressed and predicted to be 
intolerant to loss of function (probability of loss- of- function 
intolerance ≥ 0.99) according to the latest gnomAD (http://
gnomad.broadinstitute.org/about) constraint metrics (https://
www.nature.com/articles/nature19057).
3.3 | Enrichment analysis
We collected phenotypic information on seven characteris-
tics wherever this specific information was available: neuro-
logical or psychiatric disorder (528/956 patients, 55.2%), ID 
(727/944 patients, 77%), comorbidity with a nonneurologi-
cal disorder (242/882 patients, 27.4%), facial dysmorphism 
(209/769 patients, 27.2%), brain abnormalities (288/613 pa-
tients, 47%), epilepsy onset before 1 year of age (175/340 
patients, 51.5%), and diagnosis of known EE syndrome 
(238/487 patients, 49%). We compared carriers of pathogenic 
autosomal CNVs with those who did not carry a pathogenic 
autosomal CNV. Patients with pathogenic CNVs were sig-
nificantly enriched for nonneurological disorders (2.68- fold) 
and for dysmorphism (4.09- fold; Figure 2). Beyond the over-
all pathogenic CNV enrichment, testing for large pathogenic 
CNVs (>1 Mb) separately showed a more profound and 
significant fold enrichment of 2.82 and 4.94 for comorbid-
ity with nonneurological disorder and dysmorphism, respec-
tively (Figure 2).
3.4 | Meta- analysis
The search identified 4806 citations, of which 59 papers met 
the inclusion criteria and were included in the systematic 
review. Overall meta- analysis showed that in patients with 
ID without epilepsy, the yield of pathogenic CNVs was 15% 
(95% confidence interval [CI] = 14- 17), and in patients with 
psychiatric/neurological disorders without epilepsy, the yield 
was 8% (95% CI = 5- 12; Figure S3, Table 4). These data 
were compared with the two subgroups from our cohort: (1) 
patients with epilepsy and intellectual disabilities, including 
autistic features, with a yield of 13.5% (95% CI = 9.2- 18.9); 
and (2) patients with epilepsy and psychiatric/neurological 
comorbidities, with a yield of 10% (95% CI = 7.9- 11.7). 
We did not find statistically significant differences for any 
of these comparisons (P values from heterogeneity test were 
>0.05).
The yield of pathogenic CNVs in patients with epilep-
sy- EE from our cohort (7.1%, 95% CI = 4.2- 11.2) was lower, 
but not significantly different, than in patients with epilepsy- 
notEE from the meta- analysis (11%, 95% CI = 8- 14; Table 4).
4 |  DISCUSSION
Most epilepsies, especially when beginning in infancy 
and childhood, have a prominent genetic contribution. 
Numerous next generation sequencing, whole exome se-
quencing, and whole genome sequencing studies have been 
published in recent years uncovering single gene mutations 
in many epilepsies and epilepsy syndromes. Yet, the con-
tribution of CNVs to the epilepsies, especially those com-
plicated by comorbidities, has been less explored. Most 
published reports are single- center studies. The largest 
sample size was 2454 patients including a large cohort of 
1366 patients with genetic generalized epilepsy in addition 
to 281 patients with rolandic epilepsy and 807 patients with 
adult focal epilepsy28,29; the biggest cohort specifically ad-
dressing the epilepsy plus phenotype studied 222 individu-
als.4 The maximum frequency of pathogenic CNVs reported 
in any of these series was 12%, with a range of 5%- 12%. 
These studies tended to focus on individuals who were chil-
dren at the time of testing.2,5,9 The importance of rare CNVs 
has been well recognized in patients with neuropsychiatric 
disorders including unexplained ID, congenital anomalies, 
and seizures. Thus, clinical geneticists, pediatric neurolo-
gists, and epileptologists commonly request chromosomal 
array CGH to obtain a genetic diagnosis for patients with 
such clinical features.
However, CNVs may be seen in healthy control indi-
viduals, and determination of the pathogenicity of newly 
identified CNVs can be challenging. To evaluate the role 
of pathogenic CNVs and identify possible candidate genes, 
we investigated the occurrence of CNVs in epilepsy plus, 
in a cohort among the largest reported to date.2–5,9 Data 
were collected from eight centers and included both adults 
and children. Autosomal CNV classification was conducted 
using a systematic filtering procedure specifically adapted 
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T A B L E  2  CNVs including epilepsy- related genes
Individual CNV type Chr region Start Stop
Size, 
Mb Inheritance Epilepsy genes Epilepsy phenotype Other clinical features Neuroimaging
Reported epilepsy phenotype 
associated with genes
Proposed disease mechanism 
(gain or loss of function) of 
reported epilepsy genes
IT_FLO_041 Deletion 1q42- q44 236852056 249212809 12.4 De novo HNRNPU, AKT3 Epilepsy NOS, DR ID, stereotypies, congenital microceph-
aly (−4 SD), facial dysmorphism
CC agenesis, holoprosencephaly HNRNPU: epileptic encephalopathy, 
early infantile, 54 (MIM 617391) 
AKT3: megalencephaly, polymicro-
gyria, polydactyly, hydrocephalus 
syndrome 2 (MIM 615937)
Loss of function (Table S6a); 
loss and Gain of function 
(Table S6a for more details)BE_LEU_127 Duplication 1q21.1- q44 144967252 249212666 104.2 Unknown HNRNPU, AKT3 Epilepsy NOS  
with infantile  
onset, DR
Hypotonia, respiratory insufficiency, 
cardiac defects (large aorta ascendens 
and aortic arch, open ductus Botalli, 
ASD2 with small left/right shunt; 
pulmonary hypoplasia), kidney 
malrotation, facial dysmorphism
Widening of lateral ventricles and 
cavum vergae, polymicrogyria
PO_W_031 Deletion 1q43- q44 241757184 245072885 3.3 De novo HNRNPU, AKT3 Focal of unknown  
origin
ID, hypotonia, acquired microcephaly 
(−2 SD), facial dysmorphism, 
hypotonia
Frontal lobe atrophy and CC 
hypoplasia
IT_FLO_062 Deletion 1q44 244515959 247118959 2.6 De novo HNRNPU Generalized  
epilepsy, DR
ID, facial dysmorphism, GH deficit, 
deafness, acquired microcephaly 
(−2 SD), joint hyperlaxity, scoliosis
CC hypoplasia, ventricle asymmetry
BE_LEU_009 Deletion 1q44 244823848 248093878 3.3 De novo HNRNPU Lennox- Gastaut  
syndrome
ID, scoliosis, gastroesophageal reflux, 
bilateral corneal opacity
Delayed myelination, atrophic 
septum pellucidum, aqueduct 
stenosis, hydrocephaly
BE_ANT_005 Deletion 2q24.3 163860225 172528095 8.7 De novo SCN1A, SCN2A Generalized  
epilepsy of  
unknown origin
ID, facial dysmorphism Negative SCN1A: epileptic encephalopathy, 
early infantile, 6 (Dravet syndrome; 
MIM 607208); epilepsy, generalized, 
with febrile seizures plus, type 2 
(MIM 604403); febrile seizures, 
familial, 3A (MIM 604403); 
SCN2A: epileptic encephalopathy, 
early infantile, 11 (MIM 61372); 
seizures, benign familial infantile, 3 
(MIM 6077451)
Loss of function; loss of 
function is associated with 
ASD, gain of function is 
associated with EE
IT_FLO_020 Deletion 5q14.3 88232244 90181244 1.9 De novo ADGRV1 Epilepsy and  
FS NOS
None Abnormal NOS ADGRV1: febrile seizures, familial, 4 
(MIM 604352); myoclonic epilepsy 
(Table S2); 
MEF2C: mental retardation, 
stereotypic movements, epilepsy, 
and/or cerebral malformations (MIM 
613443)
Loss of function
PO_W_027 Deletion 5q14.3- q15 87100153 92514871 5.4 De novo ADGRV1, MEF2C Epilepsy NOS ID, dysmorphism NA
IT_FLO_024 Deletion 5q14q21 87770000 95780000 8 Unknown ADGRV1, MEF2C Epilepsy NOS ID, macrocephaly, facial dysmorphism Periventricular nodular heterotopia
BE_LEU_211 Deletion 5q34 161059999 161446505 0.4 Unknown GABRA1, GABRA6 Epilepsy NOS ID Corticosubcortical atrophy, 
supratentorial ventricular 
enlargement, periventricular 
vascular leukoencephalopathy, 
white matter lesions, lacunar 
infarcts in the basal ganglia and left 
thalamus
GABRA1: epileptic encephalopathy, 
early infantile, 19 (MIM 615744); 
possible susceptibility allele; juvenile 
myoclonic epilepsy (MIM 611136) 
and childhood absence epilepsy 
(MIM 611136); 
GABRA6: possible susceptibility 
allele for childhood absence epilepsy 
(Table S2)
Loss of function
PO_W_019 Deletion 9q21.13 74741400 77306932 2.6 De novo RORB Generalized  
photosensitive  
epilepsy (Jeavons  
syndrome)
ID, autism, strabismus Negative Generalized epilepsy, ID (Table S6b 
for more details)
Loss of function
BE_LEU_244 Deletion 9q21.13 76474486 81651005 5.2 Unknown RORB Generalized of  
unknown origin
ID, episodic ataxia Small nonspecific white matter 
lesions over right parietal 
hemisphere
US_267 Deletion 9q21.12-
 q21.13
72702925 77128468 4.4 Unknown RORB Generalized epilepsy  
of unknown origin
ID, pyramidal sign, tremor, neurogenic 
bladder, psychotic episodes, severe 
macrocytic anemia, cold agglutinin 
disease, bilateral femuropatellar 
arthrosis, facial dysmorphisms
NA
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T A B L E  2  CNVs including epilepsy- related genes
Individual CNV type Chr region Start Stop
Size, 
Mb Inheritance Epilepsy genes Epilepsy phenotype Other clinical features Neuroimaging
Reported epilepsy phenotype 
associated with genes
Proposed disease mechanism 
(gain or loss of function) of 
reported epilepsy genes
IT_FLO_041 Deletion 1q42- q44 236852056 249212809 12.4 De novo HNRNPU, AKT3 Epilepsy NOS, DR ID, stereotypies, congenital microceph-
aly (−4 SD), facial dysmorphism
CC agenesis, holoprosencephaly HNRNPU: epileptic encephalopathy, 
early infantile, 54 (MIM 617391) 
AKT3: megalencephaly, polymicro-
gyria, polydactyly, hydrocephalus 
syndrome 2 (MIM 615937)
Loss of function (Table S6a); 
loss and Gain of function 
(Table S6a for more details)BE_LEU_127 Duplication 1q21.1- q44 144967252 249212666 104.2 Unknown HNRNPU, AKT3 Epilepsy NOS  
with infantile  
onset, DR
Hypotonia, respiratory insufficiency, 
cardiac defects (large aorta ascendens 
and aortic arch, open ductus Botalli, 
ASD2 with small left/right shunt; 
pulmonary hypoplasia), kidney 
malrotation, facial dysmorphism
Widening of lateral ventricles and 
cavum vergae, polymicrogyria
PO_W_031 Deletion 1q43- q44 241757184 245072885 3.3 De novo HNRNPU, AKT3 Focal of unknown  
origin
ID, hypotonia, acquired microcephaly 
(−2 SD), facial dysmorphism, 
hypotonia
Frontal lobe atrophy and CC 
hypoplasia
IT_FLO_062 Deletion 1q44 244515959 247118959 2.6 De novo HNRNPU Generalized  
epilepsy, DR
ID, facial dysmorphism, GH deficit, 
deafness, acquired microcephaly 
(−2 SD), joint hyperlaxity, scoliosis
CC hypoplasia, ventricle asymmetry
BE_LEU_009 Deletion 1q44 244823848 248093878 3.3 De novo HNRNPU Lennox- Gastaut  
syndrome
ID, scoliosis, gastroesophageal reflux, 
bilateral corneal opacity
Delayed myelination, atrophic 
septum pellucidum, aqueduct 
stenosis, hydrocephaly
BE_ANT_005 Deletion 2q24.3 163860225 172528095 8.7 De novo SCN1A, SCN2A Generalized  
epilepsy of  
unknown origin
ID, facial dysmorphism Negative SCN1A: epileptic encephalopathy, 
early infantile, 6 (Dravet syndrome; 
MIM 607208); epilepsy, generalized, 
with febrile seizures plus, type 2 
(MIM 604403); febrile seizures, 
familial, 3A (MIM 604403); 
SCN2A: epileptic encephalopathy, 
early infantile, 11 (MIM 61372); 
seizures, benign familial infantile, 3 
(MIM 6077451)
Loss of function; loss of 
function is associated with 
ASD, gain of function is 
associated with EE
IT_FLO_020 Deletion 5q14.3 88232244 90181244 1.9 De novo ADGRV1 Epilepsy and  
FS NOS
None Abnormal NOS ADGRV1: febrile seizures, familial, 4 
(MIM 604352); myoclonic epilepsy 
(Table S2); 
MEF2C: mental retardation, 
stereotypic movements, epilepsy, 
and/or cerebral malformations (MIM 
613443)
Loss of function
PO_W_027 Deletion 5q14.3- q15 87100153 92514871 5.4 De novo ADGRV1, MEF2C Epilepsy NOS ID, dysmorphism NA
IT_FLO_024 Deletion 5q14q21 87770000 95780000 8 Unknown ADGRV1, MEF2C Epilepsy NOS ID, macrocephaly, facial dysmorphism Periventricular nodular heterotopia
BE_LEU_211 Deletion 5q34 161059999 161446505 0.4 Unknown GABRA1, GABRA6 Epilepsy NOS ID Corticosubcortical atrophy, 
supratentorial ventricular 
enlargement, periventricular 
vascular leukoencephalopathy, 
white matter lesions, lacunar 
infarcts in the basal ganglia and left 
thalamus
GABRA1: epileptic encephalopathy, 
early infantile, 19 (MIM 615744); 
possible susceptibility allele; juvenile 
myoclonic epilepsy (MIM 611136) 
and childhood absence epilepsy 
(MIM 611136); 
GABRA6: possible susceptibility 
allele for childhood absence epilepsy 
(Table S2)
Loss of function
PO_W_019 Deletion 9q21.13 74741400 77306932 2.6 De novo RORB Generalized  
photosensitive  
epilepsy (Jeavons  
syndrome)
ID, autism, strabismus Negative Generalized epilepsy, ID (Table S6b 
for more details)
Loss of function
BE_LEU_244 Deletion 9q21.13 76474486 81651005 5.2 Unknown RORB Generalized of  
unknown origin
ID, episodic ataxia Small nonspecific white matter 
lesions over right parietal 
hemisphere
US_267 Deletion 9q21.12-
 q21.13
72702925 77128468 4.4 Unknown RORB Generalized epilepsy  
of unknown origin
ID, pyramidal sign, tremor, neurogenic 
bladder, psychotic episodes, severe 
macrocytic anemia, cold agglutinin 
disease, bilateral femuropatellar 
arthrosis, facial dysmorphisms
NA
(Continues)
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to epilepsy. The workflow was an essential tool to identify, 
reanalyze, and reinterpret CNVs in this retrospectively col-
lected cohort, in which CNV testing had been performed 
using different platforms in different laboratories. About 11% 
of patients with epilepsy plus harbored a pathogenic autoso-
mal CNV. This number reaches 12.7% when we also consider 
the possibly pathogenic CNVs. Previous similar studies re-
port a diagnostic yield ranging from ~5% to 12%.2–5,8,9 Thus, 
our result fits at the upper limit of this range, probably mainly 
due to the “epilepsy plus” phenotype of our cohort and to the 
application of a standardized workflow. Previously published 
studies3,4,8 that reported similar yields of pathogenic CNVs 
(9.3%, 8.1%, and 12%, respectively) also examined patients 
with complex epilepsy including ID. Overall, results from 
both our and similar previous studies indicate that within the 
complex phenotype of neurodevelopmental disorders, when 
seizures are associated with ID or with other neurological and 
nonneurological comorbidities, there is a higher probability 
of identifying a pathogenic CNV than in epilepsy alone.
We checked the original classification, where available 
(138/142), of pathogenic and possibly pathogenic CNVs 
before and after applying the workflow method we propose 
here. We found that 7.2% (10/138) of cases were discrepant. 
The main direction of change was from CNVs (8/10 CNVs) 
originally classified as of “unknown significance” to “patho-
genic” and “possibly pathogenic” (Table S7). This is expected 
as information about brain- expressed genes or gene regions 
associated with epilepsy increases. We have confirmed that 
reanalysis of existing data over time is essential.
Our study confirms the importance of specific CNVs in 
epilepsy and broadens some of the associated phenotypic 
spectra.
Recurrent microdeletions at 1q21.1, 15q11.2, 15q13.3, 
16p13.11, and 22q11.21 have been reported as risk factors 
for GGEs and focal epilepsies.28,29 The most frequent CNV 
identified in our cohort was the 16p13.11 deletion, which 
accounts for 8.3% of the pathogenic CNVs, supporting a 
marked relevance in the clinical setting.
We also found several CNVs that included the genes 
HNRNPU (1q44) and RORB (9p21.13), both recently asso-
ciated with epilepsy.28,30–32 Microdeletions of the 1q43q44 
critical region have been associated with ID, dysmorphism, 
Individual CNV type Chr region Start Stop
Size, 
Mb Inheritance Epilepsy genes Epilepsy phenotype Other clinical features Neuroimaging
Reported epilepsy phenotype 
associated with genes
Proposed disease mechanism 
(gain or loss of function) of 
reported epilepsy genes
BE_LEU_205 Deletion 12p13.31 8691730 14215925 5.5 Unknown GRIN2B Focal epilepsy of  
unknown origin
ID, facial dysmorphism Negative Epileptic encephalopathy, early 
infantile, 27 (MIM 616139)
Loss and gain of function
PO_W_017 Duplication 14q11.2- q12 23309096 31675172 8.3 De novo FOXG1 Epilepsy NOS ID NA Rett syndrome, congenital variant 
(MIM 613454)
Loss of function
IT_FLO_033 Deletion 16q12.1- q21 52347499 64578499 12.2 Unknown GNAO1, GPR56 Generalized epilepsy  
of structural origin
ID, language delay, facial dysmor-
phism, microcephaly, cryptorchidism
Polymicrogyria GNAO1: epileptic encephalopathy, 
early infantile, 17 (MIM 615473); 
neurodevelopmental disorder with 
involuntary movements (MIM 
617493); movement disorder with or 
without EE; GPR56: polymicrogyria 
(MIM 606854, 615752)
Loss of function; 
gain of function (recessive, 
loss of function)
IT_FLO_017 Deletion 18q21.31-
 q21.33
54687002 59222020 4.5 Unknown NEDD4L Focal epilepsy of  
unknown origin
ID, hypotonia, dyspraxia, clumsiness, 
convergent strabismus
Vermis hypoplasia OMIM: periventricular nodular 
heterotopia (MIM 617201; 
Lennox- Gastaut syndrome–infantile 
spasms)
Loss of function
IT_FLO_074 Deletion 20q13.33 61845191 62893189 1.1 De novo KCNQ2, CHRNA4 Generalized epilepsy  
of structural origin
Bilateral deafness, facial dysmorphism, 
lumbar kyphosis, sacral dimple, 
bilateral clinodactyly, small hands and 
fingers, hypoplastic flexion creases, 
atrial and ventricular septal defects, 
left renal agenesis defects, left renal 
agenesis
Periventricular nodular heterotopia KCNQ2: epileptic encephalopathy, 
early infantile, 7 (MIM 613720); 
myokymia (MIM 121200); seizures, 
benign neonatal, 1 (MIM 121200); 
CHRNA4: epilepsy, nocturnal frontal 
lobe, 1 (MIM 600513)
Gain and loss of function; 
loss and gain of function
US_073 Deletion 21q22.3 43420839 46944323 3.5 Unknown SIK1 Generalized epilepsy  
of unknown origin
ID, ataxia, spasticity, kyphoscoliosis, 
aortic valve deficiency
Enlarged lateral ventricles with 
pronunciation of occipital horns 
(colpocephaly)
Epileptic encephalopathy, early 
infantile, 30 (MIM 616341)
Loss of function
The reported phenotype associated with each known epilepsy gene refers to the phenotype reported in the OMIM or, if not available, the citation indicated in the  
supplementary material (Table S2).
ASD, atrial septal defects; CC, corpus callosum; CNV, copy number variation; DR, drug- resistant; EE, epileptic encephalopathy; FS, febrile seizures; GH,  
growth hormone; ID, intellectual disability; MIM, Mendelian Inheritance in Man; NA, not available; NOS, not otherwise specified; OMIM,  
Online Mendelian Inheritance in Man database.
T A B L E  2  (Continued)
   | 699COPPOLA et AL.
abnormalities of the corpus callosum, and seizures.30 This 
critical region includes HNRNPU as the most relevant can-
didate epilepsy gene. Around 30 point mutations, mainly in-
cluding truncating, splice- site, and a few missense variants, 
in HNRNPU have recently been identified in individuals with 
ID and seizures (Table S6a). In our cohort, five patients car-
ried CNVs mapping to the 1q43q44 critical region, and in 
addition to the HNRNPU gene, in two duplications and one 
deletion, the chromosomal rearrangement included also the 
AKT3 gene, which might contribute to brain abnormalities 
observed in these patients. Patients with deletions showed 
dysmorphic features, early onset psychomotor delay, and 
early onset epilepsy. These data confirm the role of HNRNPU 
in neurodevelopment and epileptogenesis.
Mutations in RORB were first reported in a patient with 
mild ID and partial epilepsy.31 More recently, other muta-
tions were identified in patients with neurodevelopmental 
disorders and mostly GGE, including absence seizures (Table 
S6b). In our cohort, three patients carried deletions including 
RORB and exhibited ID and generalized epilepsy, including 
absence seizures with eyelid myoclonia, and autistic features 
in one patient, supporting a role for RORB in GGE and, more 
broadly, in several neurodevelopmental disorders.
Among the syndromic pathogenic autosomal CNVs, we 
identified three patients with duplications mapping to the 
17p11.2 Potocki- Lupski syndromic region, which is recip-
rocal to the Smith- Magenis deletion syndrome in which ep-
ilepsy is often seen.33 These three patients had a phenotype 
consistent with Potocki- Lupski syndrome; the occurrence 
of epilepsy supports previous evidence of its presence as 
a rare feature of 17p11.2 duplications.5 Interestingly, we 
identified five patients with a 7q11.23 deletion containing 
the Williams- Beuren region; four of these individuals had 
Lennox- Gastaut syndrome, and the fifth (previously re-
ported by Ramocki et al34) had a generalized drug- resistant 
epilepsy.
CNVs classified as pathogenic only because of large size 
(Table S4b) represented 27% (33/122) of all the pathogenic 
CNVs. These CNVs included a large number of genes, but 
the phenotype of affected individuals was complex and we 
were unable to identify an association with known genetic 
syndromes or with candidate epilepsy genes. However, for 
Individual CNV type Chr region Start Stop
Size, 
Mb Inheritance Epilepsy genes Epilepsy phenotype Other clinical features Neuroimaging
Reported epilepsy phenotype 
associated with genes
Proposed disease mechanism 
(gain or loss of function) of 
reported epilepsy genes
BE_LEU_205 Deletion 12p13.31 8691730 14215925 5.5 Unknown GRIN2B Focal epilepsy of  
unknown origin
ID, facial dysmorphism Negative Epileptic encephalopathy, early 
infantile, 27 (MIM 616139)
Loss and gain of function
PO_W_017 Duplication 14q11.2- q12 23309096 31675172 8.3 De novo FOXG1 Epilepsy NOS ID NA Rett syndrome, congenital variant 
(MIM 613454)
Loss of function
IT_FLO_033 Deletion 16q12.1- q21 52347499 64578499 12.2 Unknown GNAO1, GPR56 Generalized epilepsy  
of structural origin
ID, language delay, facial dysmor-
phism, microcephaly, cryptorchidism
Polymicrogyria GNAO1: epileptic encephalopathy, 
early infantile, 17 (MIM 615473); 
neurodevelopmental disorder with 
involuntary movements (MIM 
617493); movement disorder with or 
without EE; GPR56: polymicrogyria 
(MIM 606854, 615752)
Loss of function; 
gain of function (recessive, 
loss of function)
IT_FLO_017 Deletion 18q21.31-
 q21.33
54687002 59222020 4.5 Unknown NEDD4L Focal epilepsy of  
unknown origin
ID, hypotonia, dyspraxia, clumsiness, 
convergent strabismus
Vermis hypoplasia OMIM: periventricular nodular 
heterotopia (MIM 617201; 
Lennox- Gastaut syndrome–infantile 
spasms)
Loss of function
IT_FLO_074 Deletion 20q13.33 61845191 62893189 1.1 De novo KCNQ2, CHRNA4 Generalized epilepsy  
of structural origin
Bilateral deafness, facial dysmorphism, 
lumbar kyphosis, sacral dimple, 
bilateral clinodactyly, small hands and 
fingers, hypoplastic flexion creases, 
atrial and ventricular septal defects, 
left renal agenesis defects, left renal 
agenesis
Periventricular nodular heterotopia KCNQ2: epileptic encephalopathy, 
early infantile, 7 (MIM 613720); 
myokymia (MIM 121200); seizures, 
benign neonatal, 1 (MIM 121200); 
CHRNA4: epilepsy, nocturnal frontal 
lobe, 1 (MIM 600513)
Gain and loss of function; 
loss and gain of function
US_073 Deletion 21q22.3 43420839 46944323 3.5 Unknown SIK1 Generalized epilepsy  
of unknown origin
ID, ataxia, spasticity, kyphoscoliosis, 
aortic valve deficiency
Enlarged lateral ventricles with 
pronunciation of occipital horns 
(colpocephaly)
Epileptic encephalopathy, early 
infantile, 30 (MIM 616341)
Loss of function
The reported phenotype associated with each known epilepsy gene refers to the phenotype reported in the OMIM or, if not available, the citation indicated in the  
supplementary material (Table S2).
ASD, atrial septal defects; CC, corpus callosum; CNV, copy number variation; DR, drug- resistant; EE, epileptic encephalopathy; FS, febrile seizures; GH,  
growth hormone; ID, intellectual disability; MIM, Mendelian Inheritance in Man; NA, not available; NOS, not otherwise specified; OMIM,  
Online Mendelian Inheritance in Man database.
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T A B L E  3  Autosomal CNVs classified as “possibly pathogenic”
Individual CNV type Chr region Start Stop Size, Mb Inheritance Proposed candidate genesa Epilepsy phenotype Other clinical features Neuroimaging MAQ validation
BE_LEU_009 Duplication 1q43 239842929 240356854 0.5 De novo FMN2 (start BP within gene), 
CHRM3 (stop BP within 
gene)
Epilepsy NOS ID, scoliosis, gastroesophageal 
reflux, bilateral corneal 
opacity
Delayed myelination, 
atrophic septum 
pellucidum, 
aqueduct stenosis, 
hydrocephaly
De novo
US_184 Duplication 3q28 191886383 192432844 0.5 De novo FGF12 (intragenic 
duplication)
Epilepsy NOS Learning disabilities, attention 
deficit
Malrotation anterior 
and central part left 
hippocampus
NA
BE_LEU_141 Deletion 3q22.3 136035522 136412948 0.4 De novo STAG1, PCCB (start BP 
within gene)
Epilepsy NOS ID, autism, hypertonia, 
scoliosis,
NA Confirmed in patient, 
absent in mother
IT_FLO_036b Duplication 4q21.22- q21.23 84035965 84813544 0.8 De novo COQ2 (stop BP within gene) Myoclonic- atonic epilepsy ID Negative De novo
IT_FLO_127 Deletion 5q23.2 122481284 122987185 0.5 De novo CEP120, CSNK1G3 (stop BP 
within gene)
Myoclonic epilepsy ID, hypotonia Negative De novo
PO_W_039 Duplication 7q35- q36.1 146934489 148471787 1.5 Inherited (M) CNTNAP2 (start BPs within 
gene)
Epilepsy NOS ID CC hypoplasia Inconclusive
IT_FL0_131 Deletion 6q26 161725639 161878527 0.2 De novo PARK2 (stop BP within gene) Epilepsy NOS, FS ID, hypotonia, obesity 
crowding of the fingers in 
both hands and feet, 
onychodystrophy
NA Inconclusive
Deletion 12p12.3 15469971 16375910 0.9 De novo STRAP
IT_FLO_109 Duplication 8p23.3- p23.2 161272 801514 0.6 Unbalanced segregation  
of a balanced  
translocation (M)
FBXO25 Generalized epilepsy of 
unknown origin, DR
Language disorder Negative Inconclusive
IT_FLO_134 Deletion 8p23.3- 23.2 221611 801373 0.6 Unbalanced segregation  
of a balanced  
translocation (M)
FBXO25 Myoclonic epilepsy, FS No NA Inconclusive
BE_LEU_236 Duplication 9q22.31 95208377 95590171 0.4 De novo BICD2 Epilepsy NOS ID NA De novo
IT_FLO_144 Deletion 10q23.33 95490322 95791986 0.3 Inherited (M) LGI1 Epileptic encephalopathy 
NOS
Severe ID, quadriplegia, 
congenital cardiomyopathy 
(implanted pacemaker)
Cerebral atrophy 
microcephaly
Maternally inherited
BE_LEU_012 Duplication 15q13.2 32509932 1.6 Inherited (P) CHRNA7 Focal of unknown origin ID No Inconclusive
UK_L_056 Duplication 16p13.3 2481289 2888632 0.4 Unknown TBC1D24 Myoclonic- atonic epilepsy ID Negative Confirmed in proband, 
parents NA
US_175 Deletion 16p13.2 8368145 8860296 0.5 Inherited (M) ABAT (stop BP within gene) Epileptic encephalopathy 
NOS
ID, apraxia, dyskinesia, 
generalized hypotonia
Negative Maternally inherited
IT_FLO_023 Deletion 17q21.31 43160474 43922220 0.8 De novo NMT1 (start BP within gene), 
PLCD3 (start BP within 
gene)
Focal epilepsy of 
unknown origin, FS
ID, macrocephaly, facial 
dysmorphism, cardiac defect, 
skin dyschromia
CC hypoplasia Inconclusive
IT_FLO_083 Deletion 18q12.3 42605437 42784321 0.2 De novo SETBP1 (start BP within 
gene)
Generalized epilepsy of 
unknown origin, DR
ID Negative De novo
BE_LEU_116 Duplication 19p13.3 538568 2268870 1.7 Unknown HCN2 Epilepsy NOS and FS Learning disabilities, ADHD, 
facial dysmorphism
Negative Confirmed in proband, 
parents NA
US_124 Deletion 20p12.3 8314301 8688028 0.4 Inherited (M+P) PLCB1 (start BP within gene) Epileptic encephalopathy 
NOS
Profound ID, microcephaly, 
hypertonia, hyperreflexia 
more prominent on the left 
side, squint in left eye
Atrophy on CT brain NA
PO_W_030 Duplication 20q13.33 61925286 62724437 0.8 Inherited (M) KCNQ2, CHRNA4, EEF1A2 Focal epilepsy of 
unknown origin
ID, facial dysmorphism NA Confirmed in proband, 
parents NA
ADHD = attention- deficit/hyperactivity disorder; BP = breakpoint; CC = corpus callosum; CNV = copy number variation; CT = computed tomography;  
DR = drug resistant; FS = febrile seizures; ID = intellectual disability; M = maternal; MAQ = multiplex amplicon quantification; NA = not available;  
NOS = not otherwise specified; P = paternal.
aColumn with candidate genes also includes CNVs including known epilepsy genes that have not been considered pathogenic for various reasons; for example, the  
direction of the change or the phenotype did not fit to what is reported in the literature, or the CNV was inherited from a parent with unknown affectedness status. 
bReported in Ottaviani et al.43 
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T A B L E  3  Autosomal CNVs classified as “possibly pathogenic”
Individual CNV type Chr region Start Stop Size, Mb Inheritance Proposed candidate genesa Epilepsy phenotype Other clinical features Neuroimaging MAQ validation
BE_LEU_009 Duplication 1q43 239842929 240356854 0.5 De novo FMN2 (start BP within gene), 
CHRM3 (stop BP within 
gene)
Epilepsy NOS ID, scoliosis, gastroesophageal 
reflux, bilateral corneal 
opacity
Delayed myelination, 
atrophic septum 
pellucidum, 
aqueduct stenosis, 
hydrocephaly
De novo
US_184 Duplication 3q28 191886383 192432844 0.5 De novo FGF12 (intragenic 
duplication)
Epilepsy NOS Learning disabilities, attention 
deficit
Malrotation anterior 
and central part left 
hippocampus
NA
BE_LEU_141 Deletion 3q22.3 136035522 136412948 0.4 De novo STAG1, PCCB (start BP 
within gene)
Epilepsy NOS ID, autism, hypertonia, 
scoliosis,
NA Confirmed in patient, 
absent in mother
IT_FLO_036b Duplication 4q21.22- q21.23 84035965 84813544 0.8 De novo COQ2 (stop BP within gene) Myoclonic- atonic epilepsy ID Negative De novo
IT_FLO_127 Deletion 5q23.2 122481284 122987185 0.5 De novo CEP120, CSNK1G3 (stop BP 
within gene)
Myoclonic epilepsy ID, hypotonia Negative De novo
PO_W_039 Duplication 7q35- q36.1 146934489 148471787 1.5 Inherited (M) CNTNAP2 (start BPs within 
gene)
Epilepsy NOS ID CC hypoplasia Inconclusive
IT_FL0_131 Deletion 6q26 161725639 161878527 0.2 De novo PARK2 (stop BP within gene) Epilepsy NOS, FS ID, hypotonia, obesity 
crowding of the fingers in 
both hands and feet, 
onychodystrophy
NA Inconclusive
Deletion 12p12.3 15469971 16375910 0.9 De novo STRAP
IT_FLO_109 Duplication 8p23.3- p23.2 161272 801514 0.6 Unbalanced segregation  
of a balanced  
translocation (M)
FBXO25 Generalized epilepsy of 
unknown origin, DR
Language disorder Negative Inconclusive
IT_FLO_134 Deletion 8p23.3- 23.2 221611 801373 0.6 Unbalanced segregation  
of a balanced  
translocation (M)
FBXO25 Myoclonic epilepsy, FS No NA Inconclusive
BE_LEU_236 Duplication 9q22.31 95208377 95590171 0.4 De novo BICD2 Epilepsy NOS ID NA De novo
IT_FLO_144 Deletion 10q23.33 95490322 95791986 0.3 Inherited (M) LGI1 Epileptic encephalopathy 
NOS
Severe ID, quadriplegia, 
congenital cardiomyopathy 
(implanted pacemaker)
Cerebral atrophy 
microcephaly
Maternally inherited
BE_LEU_012 Duplication 15q13.2 32509932 1.6 Inherited (P) CHRNA7 Focal of unknown origin ID No Inconclusive
UK_L_056 Duplication 16p13.3 2481289 2888632 0.4 Unknown TBC1D24 Myoclonic- atonic epilepsy ID Negative Confirmed in proband, 
parents NA
US_175 Deletion 16p13.2 8368145 8860296 0.5 Inherited (M) ABAT (stop BP within gene) Epileptic encephalopathy 
NOS
ID, apraxia, dyskinesia, 
generalized hypotonia
Negative Maternally inherited
IT_FLO_023 Deletion 17q21.31 43160474 43922220 0.8 De novo NMT1 (start BP within gene), 
PLCD3 (start BP within 
gene)
Focal epilepsy of 
unknown origin, FS
ID, macrocephaly, facial 
dysmorphism, cardiac defect, 
skin dyschromia
CC hypoplasia Inconclusive
IT_FLO_083 Deletion 18q12.3 42605437 42784321 0.2 De novo SETBP1 (start BP within 
gene)
Generalized epilepsy of 
unknown origin, DR
ID Negative De novo
BE_LEU_116 Duplication 19p13.3 538568 2268870 1.7 Unknown HCN2 Epilepsy NOS and FS Learning disabilities, ADHD, 
facial dysmorphism
Negative Confirmed in proband, 
parents NA
US_124 Deletion 20p12.3 8314301 8688028 0.4 Inherited (M+P) PLCB1 (start BP within gene) Epileptic encephalopathy 
NOS
Profound ID, microcephaly, 
hypertonia, hyperreflexia 
more prominent on the left 
side, squint in left eye
Atrophy on CT brain NA
PO_W_030 Duplication 20q13.33 61925286 62724437 0.8 Inherited (M) KCNQ2, CHRNA4, EEF1A2 Focal epilepsy of 
unknown origin
ID, facial dysmorphism NA Confirmed in proband, 
parents NA
ADHD = attention- deficit/hyperactivity disorder; BP = breakpoint; CC = corpus callosum; CNV = copy number variation; CT = computed tomography;  
DR = drug resistant; FS = febrile seizures; ID = intellectual disability; M = maternal; MAQ = multiplex amplicon quantification; NA = not available;  
NOS = not otherwise specified; P = paternal.
aColumn with candidate genes also includes CNVs including known epilepsy genes that have not been considered pathogenic for various reasons; for example, the  
direction of the change or the phenotype did not fit to what is reported in the literature, or the CNV was inherited from a parent with unknown affectedness status. 
bReported in Ottaviani et al.43 
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one individual with EE and a large de novo 13q13.1- q13.3 
deletion, we can suggest that a key gene is NBEA, which was 
reported as a possible EE gene through an in silico prioritiza-
tion approach35 and was recently associated with neurodevel-
opmental disease with epilepsy.36
Four of the CNVs we classified as large and pathogenic 
were inherited. Interestingly, a duplication on 12q21.31 was 
inherited from a mother with a family history of autism. 
Autism has been reported in Decipher in a patient carry-
ing an overlapping duplication (Table S4b). Following our 
algorithm, we consider these CNVs pathogenic, noting the 
incomplete penetrance often characterizing neurological and 
epileptic disorders and because we could not exclude related 
neurological traits in the transmitting parent.
A possibly pathogenic autosomal CNV was identified in 
1.7% of the patients. As well as some known epilepsy genes, 
discussed in the results section, we propose other genes in 
these regions that can be considered potential candidates for 
causing epilepsy, but need further validation. We found a 
de novo 18q12.3 deletion, which only encompassed the gene 
SETBP1. Heterozygous missense mutations in SETBP1 cause 
Schinzel- Giedion syndrome (OMIM #269150), characterized 
by severe ID and specific craniofacial features,37 wherein sei-
zures also occur.38,39 Mutations leading to haploinsufficiency, 
such as the deletion in our patient, have been reported in asso-
ciation with a distinct neurological syndrome, which includes 
mild to moderate ID without the typical syndromic cranio-
facial features.17,40,41 The patient in this study only showed 
severe epilepsy and ID, suggesting that the SETBP1- mutation 
phenotype may be broader than previously described. One 
patient had a microdeletion, classified here as possibly patho-
genic, which includes STAG1, now linked with epilepsy as a 
cohesinopathy,24 and one patient carried a de novo intragenic 
duplication in FGF12 in which SNVs have recently been re-
ported in patients with epileptic encephalopathies.25
Other interesting candidate genes are highlighted in Table 
3 and include HCN2, FMN2, CHRM3, CSNK1G3, and NMT1.
Eleven patients (1%) in our study cohort had a double hit 
(including pathogenic and possibly pathogenic CNVs). Here, 
the CNV burden alone could contribute to the neurodevelop-
mental phenotype; as shown by Girirajan and colleagues,42 
children with two or more rare and large CNVs of unknown 
significance were eight times more likely to have develop-
mental delay compared to controls, possibly by disruption of 
dosage- sensitive genes.42 We note, however, that our analysis 
focused only on CNVs with a certain pathogenic meaning 
and as such gives no insight into the general burden of CNVs 
per patient.
T A B L E  4  Comparison of the yield of pathogenic copy number variations in three subgroups of patients from this study with respect to three 
groups of patients from the literature, analyzed through meta- analysis
Yield from this study Yield from meta- analysis
P from test of 
heterogeneityPhenotype (patients, n) Yield, % (95% CI) Phenotype Yield, % (95% CI)
a ID + epilepsy (207) 28/207 = 13.5% (9.2- 18.9) ID 15% (14- 17) 0.4491
b Psychiatric/neurological 
comorbidities + epilepsy 
(528)
53/528 = 10.0% (7.9- 11.7) Psychiatric/neurological 
disorders
8% (5- 12) 0.3962
c Epilepsy- EE (238) 17/238 = 7.1% (4.2- 11.2) Epilepsy- notEE 11% (8- 14) 0.1251
CI, confidence interval; EE, epileptic encephalopathy; ID, intellectual disability.
F I G U R E  2  Enrichment analysis. Left panel: Across all patients analyzed in this study, those affected with a pathogenic copy number 
variation (CNV) were significantly enriched for being comorbid with a nonneurological disorder or dysmorphism. Right panel: Restriction of the 
analysis to patients carrying large pathogenic CNVs (>1 Mb). These CNV carriers are particularly enriched for nonneurological disorders and 
dysmorphism. Odds ratios (ORs) significant beyond correction for multiple testing are denoted by triangles
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The enrichment analysis showed a significant association 
of pathogenic autosomal CNVs with nonneurological disor-
ders and dysmorphism (for both large pathogenic and any 
pathogenic CNV); large pathogenic CNVs showed a more 
profound and significant association with dysmorphism and 
non-neurological disorders only. An enrichment of CNVs in 
patients with dysmorphism has been observed in previous 
studies,4 underscoring the importance of testing for CNVs in 
patients with epilepsy and associated comorbidities. Likewise, 
results from our data compared to historical controls, from 
a systematic literature review and meta- analysis, confirm 
that the percentages of pathogenic CNVs, when the pheno-
type includes or excludes epilepsy, do not vary significantly. 
Thus, although a search for CNV is undoubtedly worthwhile 
in people with epilepsy plus, it may not be that such CNVs 
drive only epilepsy, but for patients ascertained through their 
epilepsy, the presence of additional features points to an el-
evated likelihood of finding an underlying pathogenic CNV. 
We hypothesize that although epilepsy as a phenotype does 
not add a quantitative contribution to the diagnostic yield, 
its presence could be related to the type, location, and gene 
content of an underlying pathogenic CNV. Results from our 
data, comparing patients with epilepsy- EE versus historical 
controls with epilepsy- notEE, showed a nonsignificantly 
lower yield of pathogenic CNVs in patients with EE, raising 
a possible hypothesis that when epilepsy manifests as EE, the 
likelihood of finding a pathogenic CNV decreases and that 
EE is more often the consequence of single gene mutations.
Our study has limitations beyond its retrospective structure. 
The filtering workflow used allowed us to obtain a system-
atic classification of the large number of CNVs examined, but 
we recognize it is not perfect and might not accurately clas-
sify CNV mapping to hypervariable chromosomal regions. 
Pathogenic CNVs could be missed due to filtering out of small 
CNVs, misclassification of abnormalities, or an incomplete list 
of genes associated with epilepsy (new epilepsy- related genes 
continue to be reported). We excluded the sex chromosomes 
from the CNV calling and subsequent analysis, because copy 
number calling from these chromosomes is prone to false- 
positive calls and might inflate the reported frequencies of di-
agnostically relevant CNVs as the X chromosome in particular 
has been associated with neurodevelopmental disorders. Also, 
recessive disease cannot be ruled out with this type of analysis 
unless the second allele is studied with another approach.
In conclusion, we highlight the pathogenic causative role 
of autosomal CNVs in almost 11% of patients (and up to 
12.7% when also considering the possibly pathogenic) with 
unexplained epilepsy with comorbidities and reiterate the 
concept that CNVs should be sought in patients with seizures 
especially when associated with other neurological and non-
neurological conditions.
This study opens new perspectives for a better understand-
ing and evaluation of CNVs identified in patients with epilepsy 
plus. We show that the reinterpretation of preexisting data 
using an adapted workflow can highlight new findings, and we 
recommend periodic systematic review of preacquired genetic 
data, as new methods and data become available. The work-
flow used here, specifically designed for epilepsy, can be used 
to homogenize data from different cohorts often collected at 
different times. Establishing the causative role of some CNVs 
can be challenging, especially when the CNV is not associated 
with a known syndrome, or similar CNVs may not be of the 
same size, might include different genes, and not have famil-
ial segregation data available to help interpretation. Bespoke, 
disease- specific algorithms may assist in assignment of CNVs 
to diagnostic categories that are more definitive than either 
“possibly pathogenic” or “of unknown significance.” There re-
main CNVs whose role will only be clarified by increasing the 
number of cases studied, functional studies, and continued ex-
change between clinicians and laboratory scientists. This study 
represents the first project of a newly formed and growing 
international consortium for CNVs in epilepsy (EpiCNV), in 
which large- scale data aggregation and sharing will be utilized 
as a new tool for CNV and gene identification in the epilepsies.
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